HHIPL1

Summary

HHIPL1 (HHIP like 1, HGNC:19710) is a protein-coding gene on chromosome 14q32.2, encoding HHIP-like protein 1 (Q96JK4).

This gene encodes a protein that belongs to the glucose/sorbosone dehydrogenase family. The encoded protein also contains a domain that binds folate and reduced folic acid derivatives.

Source: NCBI Gene 84439 — RefSeq curated summary.

At a glance

• GWAS associations: 18
• Clinical variants (ClinVar): 166 total
• MANE Select transcript: NM_001127258

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19710
Approved symbol	HHIPL1
Name	HHIP like 1
Location	14q32.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000182218
Ensembl biotype	protein_coding
Entrez	84439

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000330710, ENST00000357223, ENST00000949017

RefSeq mRNA: 3 — MANE Select: NM_001127258 NM_001127258, NM_001329411, NM_032425

CCDS: CCDS45162, CCDS9953

Canonical transcript exons

ENST00000330710 — 9 exons

Exon	Start	End
ENSE00001289954	99675091	99680569
ENSE00001293361	99668222	99668303
ENSE00001296002	99657000	99657143
ENSE00001300608	99659428	99659756
ENSE00001311914	99662876	99663021
ENSE00001318722	99672317	99672399
ENSE00001323114	99660280	99660406
ENSE00001725489	99652224	99652870
ENSE00002443954	99645129	99645462

Expression profiles

Bgee: expression breadth ubiquitous, 147 present calls, max score 75.86.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 3.9853 / max 54.2742, expressed in 1343 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
141391	1.8450	825
141389	0.7264	427
141388	0.5876	246
141390	0.4244	211
141387	0.2253	108
207370	0.1731	61
141393	0.0036	3

Top tissues by expression

241 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
caudate nucleus	UBERON:0001873	75.86	gold quality
anterior cingulate cortex	UBERON:0009835	75.73	gold quality
putamen	UBERON:0001874	74.81	gold quality
right frontal lobe	UBERON:0002810	74.69	gold quality
ventricular zone	UBERON:0003053	73.50	gold quality
amygdala	UBERON:0001876	73.42	gold quality
nucleus accumbens	UBERON:0001882	73.24	gold quality
prefrontal cortex	UBERON:0000451	73.02	gold quality
Brodmann (1909) area 9	UBERON:0013540	72.66	gold quality
stromal cell of endometrium	CL:0002255	72.21	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	70.77	gold quality
neocortex	UBERON:0001950	70.23	gold quality
frontal cortex	UBERON:0001870	69.55	gold quality
cortical plate	UBERON:0005343	68.91	gold quality
right hemisphere of cerebellum	UBERON:0014890	68.36	gold quality
cerebral cortex	UBERON:0000956	67.69	gold quality
cerebellar cortex	UBERON:0002129	67.59	gold quality
cerebellar hemisphere	UBERON:0002245	67.55	gold quality
hypothalamus	UBERON:0001898	67.06	gold quality
forebrain	UBERON:0001890	66.95	gold quality
brain	UBERON:0000955	66.14	gold quality
cerebellum	UBERON:0002037	65.88	gold quality
smooth muscle tissue	UBERON:0001135	65.79	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	65.68	gold quality
lower esophagus muscularis layer	UBERON:0035833	65.46	gold quality
ganglionic eminence	UBERON:0004023	65.43	gold quality
lower esophagus	UBERON:0013473	65.41	gold quality
Ammon’s horn	UBERON:0001954	64.95	gold quality
apex of heart	UBERON:0002098	64.85	gold quality
ascending aorta	UBERON:0001496	64.76	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.56

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

21 targeting HHIPL1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-18A-3P	99.56	65.68	1092
HSA-MIR-766-3P	99.47	65.24	1811
HSA-MIR-766-5P	99.47	67.91	2225
HSA-MIR-6852-5P	99.17	66.69	2073
HSA-MIR-6815-3P	99.13	68.98	1530
HSA-MIR-6749-3P	99.00	65.73	1443
HSA-MIR-653-3P	98.31	67.71	1542
HSA-MIR-4691-3P	98.11	66.83	1204
HSA-MIR-4443	98.02	66.25	1928
HSA-MIR-6742-3P	97.95	64.50	1490
HSA-MIR-4446-3P	97.91	64.29	991
HSA-MIR-6747-3P	97.73	64.84	1596
HSA-MIR-6779-3P	97.51	65.82	789
HSA-MIR-6515-5P	97.08	65.48	1219
HSA-MIR-1913	97.07	66.20	1417
HSA-MIR-4749-3P	96.40	66.24	798
HSA-MIR-6823-5P	96.26	65.69	919
HSA-MIR-5002-3P	95.75	67.04	542
HSA-MIR-7108-3P	94.37	64.79	183
HSA-MIR-668-5P	90.24	59.97	79

Literature-anchored findings (GeneRIF, showing 2)

• Results suggest an association of the HHIPL-1 (rs2895811) polymorphism with cardiometabolic parameters and cardiovascular risk factors in Mexican patients with myocardial infarction. (PMID:29655894)
• HHIPL1 expression was measured in coronary artery disease-relevant smooth muscle cells. (PMID:31163988)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Hhipl1	ENSMUSG00000021260
rattus_norvegicus	Hhipl1	ENSRNOG00000028390

Paralogs (2): HHIPL2 (ENSG00000143512), HHIP (ENSG00000164161)

Protein

Protein identifiers

HHIP-like protein 1 — Q96JK4 (reviewed: Q96JK4)

All UniProt accessions (2): Q96JK4, F1T0G3

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Secreted.

Similarity. Belongs to the HHIP family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q96JK4-1	1	yes
Q96JK4-2	2

RefSeq proteins (3): NP_001120730, NP_001316340, NP_115801 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001190	SRCR	Domain
IPR011041	Quinoprot_gluc/sorb_DH_b-prop	Homologous_superfamily
IPR011042	6-blade_b-propeller_TolB-like	Homologous_superfamily
IPR012938	Glc/Sorbosone_DH	Domain
IPR018143	Folate_rcpt-like	Domain
IPR036772	SRCR-like_dom_sf	Homologous_superfamily

Pfam: PF00530, PF03024, PF07995

UniProt features (18 total): disulfide bond 7, splice variant 2, compositionally biased region 2, signal peptide 1, chain 1, sequence variant 1, sequence conflict 1, domain 1, region of interest 1, glycosylation site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96JK4-F1	87.95	0.76

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (7): 484–584, 700–765, 713–775, 745–755, 181–521, 185–528, 399–417

Glycosylation sites (1): 234

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 28 (showing top): GOBP_ARTERY_DEVELOPMENT, GOBP_SMOOTHENED_SIGNALING_PATHWAY, AML1_01, chr14q32, GOBP_CIRCULATORY_SYSTEM_DEVELOPMENT, MEISSNER_NPC_HCP_WITH_H3K4ME2, MIKKELSEN_MCV6_HCP_WITH_H3K27ME3, GSE10240_CTRL_VS_IL22_STIM_PRIMARY_BRONCHIAL_EPITHELIAL_CELLS_UP, ZFP3_TARGET_GENES, MIR1913, GOBP_VASCULATURE_DEVELOPMENT, GSE12505_WT_VS_E2_2_HET_PDC_UP, LIU_OVARIAN_CANCER_TUMORS_AND_XENOGRAFTS_XDGS_DN, GOBP_CELL_MOTILITY, GSE13173_UNTREATED_VS_IL12_TREATED_ACT_CD8_TCELL_UP

GO Biological Process (5): smoothened signaling pathway (GO:0007224), cell population proliferation (GO:0008283), cell migration (GO:0016477), artery development (GO:0060840), biological_process (GO:0008150)

GO Molecular Function (2): molecular_function (GO:0003674), protein binding (GO:0005515)

GO Cellular Component (3): extracellular region (GO:0005576), membrane (GO:0016020), cellular_component (GO:0005575)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
cell surface receptor signaling pathway	1
cellular process	1
cell motility	1
blood vessel development	1
binding	1

Protein interactions and networks

STRING

656 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
HHIPL1	ADAMTS7	Q9UKP4	515
HHIPL1	ZC3HC1	Q86WB0	507
HHIPL1	WDR12	Q9GZL7	471
HHIPL1	UBE2Z	Q9H832	450
HHIPL1	CNNM2	Q9H8M5	440
HHIPL1	SMG6	Q86US8	431
HHIPL1	JCAD	Q9P266	429
HHIPL1	TCF21	O43680	419
HHIPL1	MRPS6	P82932	419
HHIPL1	MIA3	Q5JRA6	418
HHIPL1	PHACTR1	Q9C0D0	400
HHIPL1	NT5C2	P49902	391
HHIPL1	PLPP3	O14495	383
HHIPL1	COL4A1	P02462	371
HHIPL1	ANKS1A	Q92625	350

IntAct

10 interactions, top by confidence:

A	B	Type	Score
HHIPL1	CDC7	psi-mi:“MI:0914”(association)	0.350
DYM	GAPDHS	psi-mi:“MI:0914”(association)	0.350
C8B	PAPSS2	psi-mi:“MI:0914”(association)	0.350
IHO1	FAM114A1	psi-mi:“MI:0914”(association)	0.350
HHIPL1	POLRMT	psi-mi:“MI:0914”(association)	0.350
EDEM2	HIGD1C	psi-mi:“MI:0914”(association)	0.350
HHIPL1	CYTH3	psi-mi:“MI:0914”(association)	0.350
SCPEP1	CLGN	psi-mi:“MI:0914”(association)	0.350

BioGRID (28): HHIPL1 (Two-hybrid), HHIPL1 (Two-hybrid), HHIPL1 (Two-hybrid), KRTAP1-3 (Two-hybrid), HSPA5 (Affinity Capture-MS), HHIPL1 (Affinity Capture-MS), DHRS4 (Affinity Capture-MS), ACOT9 (Affinity Capture-MS), CDC7 (Affinity Capture-MS), DDX11 (Affinity Capture-MS), HHIPL1 (Affinity Capture-MS), ITPA (Affinity Capture-MS), HHIPL1 (Affinity Capture-MS), ATAD3B (Affinity Capture-MS), POLRMT (Affinity Capture-MS)

ESM2 similar proteins: B2GUY2, O18835, O35082, P04062, P17405, P17439, P18424, P22413, P57110, P58242, P82450, Q04519, Q0VD19, Q13219, Q2KHZ8, Q3MI05, Q566E5, Q5R8E3, Q5RFU0, Q5VSG8, Q6P1J0, Q6UWM7, Q6YGZ1, Q70KH2, Q71RP1, Q86Z14, Q8BYL4, Q8K1F9, Q8K3F2, Q8N119, Q8R2R1, Q8R4K8, Q8WP17, Q90YK5, Q92485, Q96JK4, Q99N32, Q9BDT0, Q9DGD1, Q9HAT2

Diamond homologs: A1L0T3, A1L1V4, A1L4H1, A5PJQ2, A6H737, A7E3W2, B4F6N6, B5DF27, B8A4W9, E1C3U7, F1QQC3, F1RD85, F7J220, G3V801, M9NDE3, O08762, O43866, O70513, P21757, P21758, P30203, P30204, P30205, P56730, P58022, P58215, P70117, P85521, Q05585, Q07797, Q08380, Q08B63, Q14DK5, Q24JV9, Q2VL90, Q2VLG4, Q2VLG6, Q2VLH6, Q4A3R3, Q4G0T1

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

166 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	153
Likely benign	6
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2076 predictions. Top by Δscore:

Variant	Effect	Δscore
14:99645459:CCAGG:C	donor_loss	1.0000
14:99645460:CAGG:C	donor_loss	1.0000
14:99645461:AGG:A	donor_loss	1.0000
14:99645462:GGT:G	donor_loss	1.0000
14:99645463:GTGA:G	donor_loss	1.0000
14:99645464:T:A	donor_loss	1.0000
14:99657144:G:GG	donor_gain	1.0000
14:99659752:TCTCA:T	donor_gain	1.0000
14:99659753:CTCA:C	donor_gain	1.0000
14:99659754:TCA:T	donor_gain	1.0000
14:99659755:CA:C	donor_gain	1.0000
14:99659755:CAGT:C	donor_loss	1.0000
14:99659756:AG:A	donor_loss	1.0000
14:99659757:G:GG	donor_gain	1.0000
14:99659758:T:A	donor_loss	1.0000
14:99660271:A:AG	acceptor_gain	1.0000
14:99660272:C:G	acceptor_gain	1.0000
14:99660275:CGCA:C	acceptor_loss	1.0000
14:99660276:GCAG:G	acceptor_loss	1.0000
14:99660277:CA:C	acceptor_loss	1.0000
14:99660278:A:AC	acceptor_loss	1.0000
14:99660278:A:AG	acceptor_gain	1.0000
14:99660278:AGAT:A	acceptor_gain	1.0000
14:99660279:G:GG	acceptor_gain	1.0000
14:99660279:GA:G	acceptor_gain	1.0000
14:99660279:GAT:G	acceptor_gain	1.0000
14:99660279:GATG:G	acceptor_gain	1.0000
14:99660279:GATGA:G	acceptor_gain	1.0000
14:99660402:AGCGG:A	donor_gain	1.0000
14:99660403:GCGG:G	donor_gain	1.0000

AlphaMissense

5074 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:99659572:G:C	W397C	0.999
14:99659572:G:T	W397C	0.999
14:99659570:T:A	W397R	0.998
14:99659570:T:C	W397R	0.998
14:99659698:G:C	W439C	0.998
14:99659698:G:T	W439C	0.998
14:99675389:G:C	W704C	0.998
14:99675389:G:T	W704C	0.998
14:99657092:A:T	D332V	0.997
14:99659696:T:A	W439R	0.997
14:99659696:T:C	W439R	0.997
14:99675365:G:C	W696C	0.997
14:99675365:G:T	W696C	0.997
14:99675540:T:A	C755S	0.997
14:99675541:G:C	C755S	0.997
14:99675600:T:A	C775S	0.997
14:99675601:G:C	C775S	0.997
14:99659576:T:C	C399R	0.996
14:99659631:G:A	C417Y	0.996
14:99660328:T:A	V475D	0.996
14:99675376:G:A	C700Y	0.996
14:99675415:G:A	C713Y	0.996
14:99675510:T:A	C745S	0.996
14:99675511:G:C	C745S	0.996
14:99659632:C:G	C417W	0.995
14:99659634:G:A	G418D	0.995
14:99660394:A:T	D497V	0.995
14:99660396:T:C	F498L	0.995
14:99660398:C:A	F498L	0.995
14:99660398:C:G	F498L	0.995

dbSNP variants (sampled 300 via entrez): RS1000010381 (14:99620338 T>C), RS1000087685 (14:99607919 G>A), RS1000178043 (14:99616857 T>C), RS1000293221 (14:99625171 G>A), RS1000304825 (14:99641892 T>A), RS1000405283 (14:99659725 C>T), RS1000409084 (14:99625490 C>T), RS1000497887 (14:99655565 A>T), RS1000576326 (14:99612357 C>G,T), RS1000577003 (14:99663795 G>A,C), RS1000625809 (14:99623903 G>A), RS1000633802 (14:99655911 C>T), RS1000679046 (14:99662059 G>A), RS1000740048 (14:99624111 T>G), RS1000775562 (14:99629767 T>G)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

18 associations (top):

Study	Trait	p-value
GCST000998_12	Coronary heart disease	1.000000e-10
GCST003116_39	Coronary artery disease	1.000000e-08
GCST003117_2	Myocardial infarction	7.000000e-06
GCST003474_8	Scalp hair shape	1.000000e-07
GCST004744_30	Lung adenocarcinoma	4.000000e-06
GCST004787_58	Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)	2.000000e-09
GCST005194_176	Coronary artery disease	5.000000e-16
GCST005195_2	Coronary artery disease	3.000000e-16
GCST005196_6	Coronary artery disease	1.000000e-14
GCST007267_141	Systolic blood pressure	5.000000e-10
GCST007269_330	Pulse pressure	2.000000e-14
GCST010058_2	Hematological and biochemical traits	4.000000e-06
GCST010479_35	Coronary artery disease	5.000000e-08
GCST010767_2	Coronary atherosclerosis (time to event)	6.000000e-08
GCST010866_58	Coronary artery disease	2.000000e-22
GCST010867_11	Coronary artery disease	6.000000e-09
GCST010867_44	Coronary artery disease	2.000000e-06
GCST011365_86	Myocardial infarction	3.000000e-09

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0006335	systolic blood pressure
EFO:0005763	pulse pressure measurement
EFO:0006944	systolic blood pressure change measurement
EFO:0004918	age at diagnosis
EFO:0007938	coronary atherosclerosis measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

13 total (human), top 13 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, increases methylation	2
terbufos	increases methylation	1
Resveratrol	decreases expression, affects cotreatment	1
Acetaminophen	decreases expression	1
Fonofos	increases methylation	1
Niclosamide	increases expression	1
Parathion	increases methylation	1
Plant Extracts	affects cotreatment, decreases expression	1
Smoke	decreases expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	increases methylation	1
Cadmium Chloride	decreases expression	1
Okadaic Acid	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer